See more : RiverNorth Opportunities Fund, Inc. (RIV-PA) Income Statement Analysis – Financial Results
Complete financial analysis of ProQR Therapeutics N.V. (PRQR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProQR Therapeutics N.V., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Unggul Indah Cahaya Tbk (UNIC.JK) Income Statement Analysis – Financial Results
- Fresenius SE & Co. KGaA (FSNUF) Income Statement Analysis – Financial Results
- NH Hotel Group, S.A. (0OHG.L) Income Statement Analysis – Financial Results
- Shilp Gravures Limited (SHILGRAVQ.BO) Income Statement Analysis – Financial Results
- Danske Invest Mix Obligationer (DKIMOB.CO) Income Statement Analysis – Financial Results
ProQR Therapeutics N.V. (PRQR)
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 4.04M | 1.35M | 0.00 | 1.93M | 4.94M | -1.53M | 2.28M | 9.41M | 313.00K | 0.00 |
| Cost of Revenue | 133.52K | 2.48M | 0.00 | 2.19M | 116.82M | 983.51K | 1.00M | 1.28M | 482.85K | 0.00 | 0.00 |
| Gross Profit | 6.38M | 1.56M | 1.35M | -2.19M | -114.89M | 3.96M | -2.53M | 1.00M | 8.92M | 313.00K | 0.00 |
| Gross Profit Ratio | 97.95% | 38.68% | 100.00% | 0.00% | -5,943.61% | 80.09% | 165.49% | 43.84% | 94.87% | 100.00% | 0.00% |
| Research & Development | 25.15M | 50.87M | 42.22M | 38.14M | 46.49M | 29.51M | 31.15M | 31.92M | 23.40M | 10.27M | 2.57M |
| General & Administrative | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Other Expenses | -3.01M | -765.00K | -1.04M | 9.37M | 1.93M | 5.76M | 1.50M | 1.83M | 3.24M | 313.00K | 0.00 |
| Operating Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Cost & Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Interest Income | 2.59M | 106.00K | 5.00K | 313.00K | 402.00K | -792.00K | -3.18M | 470.00K | 6.17M | 4.33M | 24.00K |
| Interest Expense | 1.20M | 5.13M | 3.41M | 2.04M | 1.08M | 810.00K | 596.00K | 538.00K | 395.00K | 265.00K | 38.00K |
| Depreciation & Amortization | 2.51M | 2.48M | 2.42M | 2.19M | 2.05M | 983.51K | 1.00M | 1.28M | 480.00K | 126.00K | 24.00K |
| EBITDA | -24.10M | -56.46M | -54.95M | -136.56M | -174.27M | -35.29M | 0.00 | -120.55M | -84.24M | -49.70M | -3.19M |
| EBITDA Ratio | -369.93% | -1,470.99% | -4,089.81% | 0.00% | -2,965.65% | -831.05% | 2,676.78% | -1,759.68% | -316.34% | -5,318.85% | 0.00% |
| Operating Income | -31.86M | -64.72M | -57.19M | -42.37M | -57.45M | -36.29M | -40.50M | -39.57M | -27.00M | -16.46M | -3.24M |
| Operating Income Ratio | -489.09% | -1,603.07% | -4,223.86% | 0.00% | -2,971.81% | -734.53% | 2,648.66% | -1,734.14% | -287.05% | -5,259.11% | 0.00% |
| Total Other Income/Expenses | 4.05M | 1.05M | -3.47M | -4.12M | 117.65M | -792.00K | 850.31K | 470.00K | 6.17M | 4.33M | -14.00K |
| Income Before Tax | -27.81M | -64.80M | -61.56M | -46.49M | -56.61M | -37.09M | -43.67M | -39.10M | -20.83M | -12.13M | -3.25M |
| Income Before Tax Ratio | -426.97% | -1,605.03% | -4,546.75% | 0.00% | -2,928.82% | -750.56% | 2,856.31% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| Income Tax Expense | -78.00K | 96.00K | 117.00K | 124.00K | 132.00K | 1.00K | 2.00K | -470.00K | -6.17M | -4.33M | 24.00K |
| Net Income | -28.12M | -64.89M | -61.68M | -46.61M | -56.75M | -36.89M | -43.64M | -39.10M | -20.83M | -12.13M | -3.25M |
| Net Income Ratio | -431.67% | -1,607.41% | -4,555.39% | 0.00% | -2,935.64% | -746.69% | 2,853.96% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| EPS | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| EPS Diluted | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| Weighted Avg Shares Out | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
| Weighted Avg Shares Out (Dil) | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
ProQR Announces Virtual Presentation at EURETINA 2021
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a virtual oral presentation of data from...
ProQR Announces Upcoming Investor Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management...
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management...
ProQR Announces Second Quarter 2021 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and...
ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
PRQR is using antisense RNA technology to target inherited retinal diseases. They have strong data from one indication, and decent data from another.
PRQR Stock: From $6.36 To $6.81 (7.08% Increase) Pre-Market Explanation
The stock price of ProQR Therapeutics N.V. (NASDAQ: PRQR) increased from $6.36 to $6.81 (up 7.08%) pre-market.
Alphabet, Costco, FedEx, UPS and More Monday Afternoon Analyst Calls
With the trading day more than halfway over, the broad markets were somewhat mixed on the day.
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual oral presentation of data...
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the publication in the scientific journal...
An End to This Rare Syndrome Could Be an Opportunity for Investors
A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.
Source: https://incomestatements.info
Category: Stock Reports